2Sims R, Weaver B, Caldwell J, et al. University of Alabama School of Medicine[J]. Acad Med, 2004,79 (7 Suppl) :S1-2.
3de Azevedo WF Jr, Dias R. Computational methods for calculation of ligand binding affinity[J]. Curr Drug Targets,2008,9(12) :1031 -1039.
4Thomas G. Fundamentals of medicinal chemistry [M]. Hoboken:John Wiley and Sons Ltd,2003.
5Ge P,Tsao J,Schein S,et al. Cryo-EM model of the bullet-shaped vesicular stomatitis virus[J]. Science, 2010,327 (5966) :689-693.
6Cyranoski D. Threat of pandemic brings flu drug back to life[J]. Nat Med,2005,11(9) :909.
7Scheinfeld N. A comprehensive review of imatinib mesy- late (Gleevec) for dermatological diseases [J]. J Drugs Dermatol, 2006,5(2) : 117-122.
8Rayburn ER, Ezell SJ,Zhang R. Recent advances in validating MDM2 as a cancer target[J]. Anticancer Agents Med Chem,2009,9(8):882- 903.
9Jia L, Gorman GS, Coward LU, et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin p28 (NSC745104) a peptide inhibitor of p53 ubiquitination [J]. Cancer Chemother Pharmacol,2010 Nov 18.
